Primary Sclerosing Cholangitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major primary sclerosing cholangitis markets are expected to exhibit a CAGR of 5.84% during 2024-2034.
The primary sclerosing cholangitis market has been comprehensively analyzed in IMARC's new report titled "Primary Sclerosing Cholangitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary sclerosing cholangitis (PSC) refers to a chronic liver disease characterized by inflammation, scarring, and narrowing of the bile ducts inside as well as outside the liver. Some of the common symptoms include fatigue, itching (pruritus), abdominal pain or discomfort, jaundice, dark urine, pale stools, unintended weight loss, etc. These indications can vary in severity and may be intermittent. Additionally, the ailment is often associated with inflammatory bowel disease, particularly ulcerative colitis, and individuals suffering from PSC may experience various related symptoms, such as diarrhea, rectal bleeding, abdominal cramping, etc. Diagnosing primary sclerosing cholangitis involves a combination of clinical evaluation, imaging studies, and laboratory procedures. The diagnostic process typically begins with a thorough medical history and physical examination, followed by blood tests to assess liver function and identify specific serological markers associated with PSC. Numerous imaging techniques, including magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography, are used to visualize the bile ducts and check for characteristic abnormalities like strictures or narrowing. Additionally, a liver biopsy may be performed in certain cases to confirm the diagnosis or rule out other liver conditions.
The increasing cases of immune system dysfunction in which the immune system mistakenly attacks the bile ducts, thereby leading to inflammation and scarring, are primarily driving the primary sclerosing cholangitis market. Besides this, the rising prevalence of several associated risk factors, such as alterations in the composition and function of the gut microbiota, chronic inflammation in the bile ducts, genetic predisposition, a history of chronic bacterial cholangitis, etc., is propelling the market growth. Additionally, the widespread adoption of antibiotics, including ciprofloxacin and trimethoprim, for managing bacterial infections and preventing recurrent episodes of cholangitis is acting as another significant growth-inducing factor. Apart from this, the escalating application of immune modulators, such as obeticholic acid (OCA) and fibrates, to modulate the immune response and reduce liver inflammation in patients is also bolstering the market growth. Furthermore, the ongoing advancements in endoscopic techniques, including the introduction of digital cholangioscopy and single-operator cholangioscopy, which enable the removal of bile duct stones, biopsy of suspicious lesions, and dilation of strictures with improved precision, are expected to drive the primary sclerosing cholangitis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the primary sclerosing cholangitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary sclerosing cholangitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary sclerosing cholangitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the primary sclerosing cholangitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the primary sclerosing cholangitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current primary sclerosing cholangitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the primary sclerosing cholangitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the primary sclerosing cholangitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the primary sclerosing cholangitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of primary sclerosing cholangitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary sclerosing cholangitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary sclerosing cholangitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with primary sclerosing cholangitis across the seven major markets?
What is the size of the primary sclerosing cholangitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of primary sclerosing cholangitis?
What will be the growth rate of patients across the seven major markets?
Primary Sclerosing Cholangitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for primary sclerosing cholangitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary sclerosing cholangitis market?
What are the key regulatory events related to the primary sclerosing cholangitis market?
What is the structure of clinical trial landscape by status related to the primary sclerosing cholangitis market?
What is the structure of clinical trial landscape by phase related to the primary sclerosing cholangitis market?
What is the structure of clinical trial landscape by route of administration related to the primary sclerosing cholangitis market?
The primary sclerosing cholangitis market has been comprehensively analyzed in IMARC's new report titled "Primary Sclerosing Cholangitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary sclerosing cholangitis (PSC) refers to a chronic liver disease characterized by inflammation, scarring, and narrowing of the bile ducts inside as well as outside the liver. Some of the common symptoms include fatigue, itching (pruritus), abdominal pain or discomfort, jaundice, dark urine, pale stools, unintended weight loss, etc. These indications can vary in severity and may be intermittent. Additionally, the ailment is often associated with inflammatory bowel disease, particularly ulcerative colitis, and individuals suffering from PSC may experience various related symptoms, such as diarrhea, rectal bleeding, abdominal cramping, etc. Diagnosing primary sclerosing cholangitis involves a combination of clinical evaluation, imaging studies, and laboratory procedures. The diagnostic process typically begins with a thorough medical history and physical examination, followed by blood tests to assess liver function and identify specific serological markers associated with PSC. Numerous imaging techniques, including magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography, are used to visualize the bile ducts and check for characteristic abnormalities like strictures or narrowing. Additionally, a liver biopsy may be performed in certain cases to confirm the diagnosis or rule out other liver conditions.
The increasing cases of immune system dysfunction in which the immune system mistakenly attacks the bile ducts, thereby leading to inflammation and scarring, are primarily driving the primary sclerosing cholangitis market. Besides this, the rising prevalence of several associated risk factors, such as alterations in the composition and function of the gut microbiota, chronic inflammation in the bile ducts, genetic predisposition, a history of chronic bacterial cholangitis, etc., is propelling the market growth. Additionally, the widespread adoption of antibiotics, including ciprofloxacin and trimethoprim, for managing bacterial infections and preventing recurrent episodes of cholangitis is acting as another significant growth-inducing factor. Apart from this, the escalating application of immune modulators, such as obeticholic acid (OCA) and fibrates, to modulate the immune response and reduce liver inflammation in patients is also bolstering the market growth. Furthermore, the ongoing advancements in endoscopic techniques, including the introduction of digital cholangioscopy and single-operator cholangioscopy, which enable the removal of bile duct stones, biopsy of suspicious lesions, and dilation of strictures with improved precision, are expected to drive the primary sclerosing cholangitis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the primary sclerosing cholangitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary sclerosing cholangitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary sclerosing cholangitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the primary sclerosing cholangitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the primary sclerosing cholangitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current primary sclerosing cholangitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the primary sclerosing cholangitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the primary sclerosing cholangitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the primary sclerosing cholangitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of primary sclerosing cholangitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary sclerosing cholangitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary sclerosing cholangitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with primary sclerosing cholangitis across the seven major markets?
What is the size of the primary sclerosing cholangitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of primary sclerosing cholangitis?
What will be the growth rate of patients across the seven major markets?
Primary Sclerosing Cholangitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for primary sclerosing cholangitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary sclerosing cholangitis market?
What are the key regulatory events related to the primary sclerosing cholangitis market?
What is the structure of clinical trial landscape by status related to the primary sclerosing cholangitis market?
What is the structure of clinical trial landscape by phase related to the primary sclerosing cholangitis market?
What is the structure of clinical trial landscape by route of administration related to the primary sclerosing cholangitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRIMARY SCLEROSING CHOLANGITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRIMARY SCLEROSING CHOLANGITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRIMARY SCLEROSING CHOLANGITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PRIMARY SCLEROSING CHOLANGITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRIMARY SCLEROSING CHOLANGITIS - UNMET NEEDS
10 PRIMARY SCLEROSING CHOLANGITIS - KEY ENDPOINTS OF TREATMENT
11 PRIMARY SCLEROSING CHOLANGITIS - MARKETED PRODUCTS
11.1 List of Primary Sclerosing Cholangitis Marketed Drugs Across the Top 7 Markets
11.1.1 Urso Forte (Ursodeoxycholic acid) - Alfa Farmaceutici/sanofi-aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PRIMARY SCLEROSING CHOLANGITIS - PIPELINE DRUGS
12.1 List of Primary Sclerosing Cholangitis Pipeline Drugs Across the Top 7 Markets
12.1.1 A3907 - Albireo Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Volixibat - Mirum Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 PLN 74809 - Pliant Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Cilofexor - Gilead Sciences/Phenex Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Seladelpar - CymaBay Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PRIMARY SCLEROSING CHOLANGITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRIMARY SCLEROSING CHOLANGITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRIMARY SCLEROSING CHOLANGITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Primary Sclerosing Cholangitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Primary Sclerosing Cholangitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Primary Sclerosing Cholangitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Primary Sclerosing Cholangitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Primary Sclerosing Cholangitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Primary Sclerosing Cholangitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Primary Sclerosing Cholangitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Primary Sclerosing Cholangitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
16 PRIMARY SCLEROSING CHOLANGITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRIMARY SCLEROSING CHOLANGITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRIMARY SCLEROSING CHOLANGITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRIMARY SCLEROSING CHOLANGITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRIMARY SCLEROSING CHOLANGITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRIMARY SCLEROSING CHOLANGITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PRIMARY SCLEROSING CHOLANGITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRIMARY SCLEROSING CHOLANGITIS - UNMET NEEDS
10 PRIMARY SCLEROSING CHOLANGITIS - KEY ENDPOINTS OF TREATMENT
11 PRIMARY SCLEROSING CHOLANGITIS - MARKETED PRODUCTS
11.1 List of Primary Sclerosing Cholangitis Marketed Drugs Across the Top 7 Markets
11.1.1 Urso Forte (Ursodeoxycholic acid) - Alfa Farmaceutici/sanofi-aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PRIMARY SCLEROSING CHOLANGITIS - PIPELINE DRUGS
12.1 List of Primary Sclerosing Cholangitis Pipeline Drugs Across the Top 7 Markets
12.1.1 A3907 - Albireo Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Volixibat - Mirum Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 PLN 74809 - Pliant Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Cilofexor - Gilead Sciences/Phenex Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Seladelpar - CymaBay Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PRIMARY SCLEROSING CHOLANGITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRIMARY SCLEROSING CHOLANGITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRIMARY SCLEROSING CHOLANGITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Primary Sclerosing Cholangitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Primary Sclerosing Cholangitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Primary Sclerosing Cholangitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Primary Sclerosing Cholangitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Primary Sclerosing Cholangitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Primary Sclerosing Cholangitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Primary Sclerosing Cholangitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Primary Sclerosing Cholangitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Primary Sclerosing Cholangitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Primary Sclerosing Cholangitis - Access and Reimbursement Overview
16 PRIMARY SCLEROSING CHOLANGITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRIMARY SCLEROSING CHOLANGITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRIMARY SCLEROSING CHOLANGITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
